Sava Raises $19 Million to Pioneer Real-Time Molecular Health Monitoring

Sava Technologies, developer of the world’s first multi-molecule biosensor capable of detecting biomarkers just under the skin in real-time, founded by Renato Circi and Rafaël Michali, has raised $19 million in Series A funding, following promising early results from its clinical trial. The round was led by Balderton Capital and Pentland Ventures, with strong participation from new investors Norrsken VC and JamJar Investments. They were joined by other investors, including True, Italian Founders Fund, Athletico Ventures, SOLO Investments, and Exceptional Ventures, bringing the company's total funding to $32 million. The round will help Sava accelerate regulatory approval and commercialisation of its next-generation wearable.

Sava is building a real-time, multi-molecule biosensor platform to enable preventative and personalized healthcare, starting with a pain-free, low-cost continuous glucose monitor that delivers molecular insights directly to your phone.

Sava’s independent clinical trial in Oxford and Cambridge showed its microsensor reliably delivered accurate glucose readings for up to 10 days—doubling the lifespan of most current systems. The results mark a major step toward regulatory approval and pave the way for a pivotal study next year.

Despite generating over $11B annually, current CGMs are used by just 1% of people with diabetes due to pain, cost, and accessibility. Sava aims to change that with a pain-free, affordable, and scalable alternative designed to drive broader adoption and transform diabetes care.

Sava’s modular sensing platform goes beyond glucose, enabling real-time monitoring of multiple biomarkers for personalized, preventative health. With rising interest from athletes and health-conscious consumers, the company is poised to expand into the $100B+ global wearables market by 2029.